GKOS Logo

Glaukos Corporation (GKOS) 

NYSE
Market Cap
$7.94B
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
539 of 774
Rank in Industry
65 of 99

Largest Insider Buys in Sector

GKOS Stock Price History Chart

GKOS Stock Performance

About Glaukos Corporation

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; …

Insider Activity of Glaukos Corporation

Over the last 12 months, insiders at Glaukos Corporation have bought $0 and sold $61.86M worth of Glaukos Corporation stock.

On average, over the past 5 years, insiders at Glaukos Corporation have bought $0 and sold $20.27M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 4,200 shares for transaction amount of $100,128 was made by Gilliam Joseph E () on 2017‑11‑22.

List of Insider Buy and Sell Transactions, Glaukos Corporation

2024-10-30SalePRESIDENT & COO
2,275
0.0041%
$138.97$316,157+1.55%
2024-09-09Saledirector
3,000
0.0055%
$130.67$392,000+0.49%
2024-08-21SalePRESIDENT & COO
5,000
0.0091%
$129.36$646,791+0.22%
2024-08-15Saledirector
6,250
0.0118%
$125.93$787,0860.00%
2024-08-08Saledirector
25,000
0.0453%
$120.00$3M+7.96%
2024-07-05SalePRESIDENT & COO
2,250
0.0046%
$121.39$273,1280.00%
2024-06-03SalePRESIDENT & COO
2,500
0.0049%
$113.50$283,751+11.31%
2024-05-30Saledirector
5,000
0.01%
$112.00$560,000+14.45%
2024-05-15Saledirector
6,250
0.0126%
$112.80$704,993+13.39%
2024-05-10SalePRESIDENT & COO
2,395
0.0048%
$110.56$264,791+13.83%
2024-05-10SaleSVP & CHIEF FINANCIAL OFFICER
316
0.0006%
$110.43$34,896+13.83%
2024-05-10SaleSVP & CHIEF FINANCIAL OFFICER
353
0.0007%
$110.51$39,011+13.83%
2024-05-06SalePRESIDENT & COO
105
0.0002%
$110.36$11,588+18.74%
2024-05-06SaleSVP & CHIEF FINANCIAL OFFICER
90
0.0002%
$110.26$9,923+18.74%
2024-05-02SalePRESIDENT & COO
2,059
0.0041%
$105.52$217,263+18.21%
2024-05-02SaleSVP & CHIEF FINANCIAL OFFICER
442
0.0009%
$105.69$46,713+18.21%
2024-04-08SalePRESIDENT & COO
59,801
0.1207%
$100.47$6.01M+19.07%
2024-04-08SaleSVP & CHIEF FINANCIAL OFFICER
1,372
0.0028%
$100.54$137,944+19.07%
2024-04-05SalePRESIDENT & COO
2,457
0.005%
$96.81$237,862+23.75%
2024-04-05SaleSVP & CHIEF FINANCIAL OFFICER
262
0.0005%
$96.63$25,316+23.75%

Insider Historical Profitability

40.06%
Gilliam Joseph EPRESIDENT & COO
102169
0.1853%
$144.00139+49.43%
Burns Thomas WilliamCHAIRMAN & CEO
55835
0.1013%
$144.00145+18.1%
WEISNER AIMEE Sdirector
30119
0.0546%
$144.0021+57.32%
MORE ROBERT Jdirector
5000
0.0091%
$144.0010
HARRISON RICHARD L
1388
0.0025%
$144.0018+18.1%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$744.61M15.687.9M+0.03%+$255,997.350.02
Fidelity Investments$693.68M14.617.36M+26.43%+$145M0.05
The Vanguard Group$500.58M10.545.31M+1.38%+$6.8M0.01
Brown Capital Management$201.11M4.242.13M-20.94%-$53.27M3.57
State Street$172.15M3.631.83M+0.48%+$829,657.710.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.